CN105163724A - 包含囊泡的药物组合物 - Google Patents

包含囊泡的药物组合物 Download PDF

Info

Publication number
CN105163724A
CN105163724A CN201480017087.1A CN201480017087A CN105163724A CN 105163724 A CN105163724 A CN 105163724A CN 201480017087 A CN201480017087 A CN 201480017087A CN 105163724 A CN105163724 A CN 105163724A
Authority
CN
China
Prior art keywords
vesicles
composition
animal
vesicle
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480017087.1A
Other languages
English (en)
Chinese (zh)
Inventor
G.格兰迪
A.格兰迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Externautics SpA
Original Assignee
GlaxoSmithKline Biologicals SA
Externautics SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA, Externautics SpA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN105163724A publication Critical patent/CN105163724A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
CN201480017087.1A 2013-02-07 2014-02-06 包含囊泡的药物组合物 Pending CN105163724A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13154463 2013-02-07
EP13154463.7 2013-02-07
PCT/EP2014/052370 WO2014122232A1 (en) 2013-02-07 2014-02-06 Pharmaceutical compositions comprising vesicles

Publications (1)

Publication Number Publication Date
CN105163724A true CN105163724A (zh) 2015-12-16

Family

ID=47681775

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480017087.1A Pending CN105163724A (zh) 2013-02-07 2014-02-06 包含囊泡的药物组合物

Country Status (7)

Country Link
US (1) US20160120818A1 (https=)
EP (1) EP2953620A1 (https=)
JP (1) JP2016507543A (https=)
CN (1) CN105163724A (https=)
BR (1) BR112015018877A2 (https=)
CA (1) CA2900454A1 (https=)
WO (1) WO2014122232A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110248645A (zh) * 2016-12-29 2019-09-17 韩国科学技术研究院 新型的基于外来体的抗癌剂
CN110367202A (zh) * 2019-06-20 2019-10-25 广东医科大学附属医院 一种肠菌外膜囊泡在制备痴呆动物模型中的应用
WO2021031409A1 (zh) * 2019-08-22 2021-02-25 四川大学 铜绿假单胞菌疫苗在呼吸系统疾病中的应用
WO2023097652A1 (en) * 2021-12-03 2023-06-08 National Center For Nanoscience And Technology An engineered cell and application thereof
CN120789140A (zh) * 2025-09-12 2025-10-17 湖北医药学院 一种治疗结肠炎的联合用药物及其应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037503B1 (ru) * 2014-01-21 2021-04-05 Анджариум Байосайенсиз Аг Способ получения гибридосомы, гибридосома, полученная при помощи способа, и способ доставки терапевтического или диагностического средства
CN106999444B (zh) * 2014-10-03 2023-12-12 安吉尼科分子传输公司 完整的细菌衍生的囊泡对小分子化合物的增强装载
US20190091307A1 (en) * 2016-03-03 2019-03-28 Institut Gustave Roussy Ptps-based vaccines against cancer
US11524037B2 (en) 2017-09-08 2022-12-13 Evelo Biosciences, Inc. Bacterial extracellular vesicles
BR102018008194A2 (pt) * 2018-04-24 2020-07-07 Universidade De São Paulo - Usp. kit farmacêutico e seus usos
WO2019210189A1 (en) * 2018-04-26 2019-10-31 University Of Louisville Research Foundation, Inc. Edible plant exosome-like nanovectors for vaccination
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020146390A1 (en) * 2019-01-09 2020-07-16 Exocure Biosciences, Inc. Bacteria-derived vesicles and uses thereof
EP4013392B1 (en) 2019-09-13 2026-04-29 Exocure Sweden AB Use of ghost nanovesicles as therapeutics
CN111521826A (zh) * 2020-05-21 2020-08-11 江海松 外周血外泌体中Notch3蛋白作为分子标记的应用及一种检测试剂盒
WO2022154149A1 (ko) * 2021-01-14 2022-07-21 (주)엑솔런스 세포외소포체를 이용한 백신 조성물
KR20240010702A (ko) * 2022-07-13 2024-01-24 (주)엑솔런스 항원 단백질 또는 상기 단백질을 암호화하는 유전자를포함하는 세포외소포체 및 그의 용도
CN115350161B (zh) * 2022-08-19 2024-04-16 沈阳药科大学 基于工程化益生菌外膜囊泡包被纳米酶递送系统及其制备方法和应用
CN117065041B (zh) * 2023-04-04 2024-02-27 山东大学 一种包被载药脂质纳米粒的外膜囊泡及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052885A1 (en) * 2000-01-17 2001-07-26 Chiron Spa Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
WO2005079854A1 (en) * 2004-02-02 2005-09-01 Engeneic Molecular Delivery Pty Ltd. Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
WO2006046143A2 (en) * 2004-10-29 2006-05-04 Novartis Vaccines And Diagnostics Srl Immunogenic bacterial vesicles with outer membrane proteins
CN102596177A (zh) * 2009-07-01 2012-07-18 阿昂梅迪克斯公司 来源于有核哺乳动物细胞的微囊泡及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
AU762369B2 (en) 1998-11-03 2003-06-26 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur LPS with reduced toxicity from genetically modified gram negative bacteria
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
US6936261B2 (en) 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0130123D0 (en) * 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
EP1524991A1 (en) 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2616294T3 (es) 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
CN102014934B (zh) * 2008-02-22 2014-08-20 新加坡科技研究局 间充质干细胞颗粒
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052885A1 (en) * 2000-01-17 2001-07-26 Chiron Spa Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
CN102172398A (zh) * 2000-01-17 2011-09-07 诺华疫苗和诊断有限公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
WO2005079854A1 (en) * 2004-02-02 2005-09-01 Engeneic Molecular Delivery Pty Ltd. Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
WO2006046143A2 (en) * 2004-10-29 2006-05-04 Novartis Vaccines And Diagnostics Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101048175A (zh) * 2004-10-29 2007-10-03 启龙有限公司 具有外膜蛋白的免疫原性细菌囊泡
CN102596177A (zh) * 2009-07-01 2012-07-18 阿昂梅迪克斯公司 来源于有核哺乳动物细胞的微囊泡及其应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHENJIE YANG ET AL.: ""The roles of tumor-derived exosomes in cancer pathogenesis"", 《CLINICAL AND DEVELOPMENTAL IMMUNOLOGY》 *
DONG HO LEE ET AL.: ""Adjuvant effect of bacterial outer membrane vesicles with penta-acylated lipopolysaccharide on antigen-specific T cell priming"", 《VACCINE》 *
JOSEPH WOLFERS ET AL.: ""Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming"", 《NATURE PUBLISHING GROUP》 *
RIENK NIEUWLAND ET AL.: ""Why do cells release vesicles?"", 《THROMBOSIS RESEARCH》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110248645A (zh) * 2016-12-29 2019-09-17 韩国科学技术研究院 新型的基于外来体的抗癌剂
CN110248645B (zh) * 2016-12-29 2022-04-26 韩国科学技术研究院 基于外来体的抗癌剂
CN110367202A (zh) * 2019-06-20 2019-10-25 广东医科大学附属医院 一种肠菌外膜囊泡在制备痴呆动物模型中的应用
WO2021031409A1 (zh) * 2019-08-22 2021-02-25 四川大学 铜绿假单胞菌疫苗在呼吸系统疾病中的应用
WO2023097652A1 (en) * 2021-12-03 2023-06-08 National Center For Nanoscience And Technology An engineered cell and application thereof
CN120789140A (zh) * 2025-09-12 2025-10-17 湖北医药学院 一种治疗结肠炎的联合用药物及其应用

Also Published As

Publication number Publication date
JP2016507543A (ja) 2016-03-10
US20160120818A1 (en) 2016-05-05
WO2014122232A1 (en) 2014-08-14
EP2953620A1 (en) 2015-12-16
BR112015018877A2 (pt) 2017-08-22
CA2900454A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
CN105163724A (zh) 包含囊泡的药物组合物
JP7244124B2 (ja) 生体高分子薬を送達するための組成物及び方法
Zhu et al. Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity
US12054521B2 (en) FhuD2 fusion proteins for the outer membrane vesicle (OMV) delivery of heterologous polypetides and immunogenic compositions thereof
JP5755839B2 (ja) Ｔ細胞応答の増強方法
Altin et al. Liposomal vaccines—targeting the delivery of antigen
JP5781929B2 (ja) 免疫原性の両親媒性ペプチド組成物
ES2401706T3 (es) Un método de tratar células cancerosas para crear una célula cancerosa modificada que provoca una respuesta inmunogénica
US11066453B2 (en) Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
Granadillo et al. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice
Moore et al. Injectable, ribbon-like microconfetti biopolymer platform for vaccine applications
Kumar et al. Development of soluble inulin microparticles as a potent and safe vaccine adjuvant and delivery system
Yan et al. The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome
Arias et al. Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen
Wang et al. A natural IgM hitchhiking strategy for delivery of cancer nanovaccines to splenic marginal zone B cells
Kuai et al. Lipid-based nanoparticles for vaccine applications
TWI916817B (zh) 一種針對ＭＩＣＡ/Ｂ靶點的ｍＲＮＡ腫瘤疫苗
WO2004033483A2 (en) Liposomal system and method of using same
Paterson Rational approaches to immune regulation
Gayatri et al. Utilization of Protein and Peptides as Cancer Vaccines: Advancement and Challenges Assessment of Ethnomedicinal Plants: Shiwalik Hills, Himachal Pradesh, India
Zhang et al. Adjuvant Delivery Method and Nanoparticle Charge Influence Peptide Amphiphile Micelle Vaccine Bioactivity
Altin Liposomes and other nanoparticles as cancer vaccines and immunotherapeutics
AU2014201422B2 (en) A method for enhancing T cell response
Chesson Supramolecular Peptide Nanofiber Vaccines for Eliciting CD8+ T-cell Responses
Trent A modular, multivalent, and multifunctional vaccine platform based on self-assembled peptide amphiphile micelles

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151216